Replies to post #89196 on Biotech Values

[mcbio]

Re: GNVC NVS collaboration

GNVC, NVS Ink Collaboration to Treat Hearing Loss

[The program is in the preclinical stage. Up-front cash is $7M, including $2M for an equity purchase by NVS; potential clinical, regulatory, and sales-based milestones are $214M.]

This sounds like a fairly interesting and novel program as it's not too often you hear about someone working in the area of hearing loss. As you noted, though, it's only at the pre-clinical stage and very likely only serves as a very small iron in the fire in the event of failure in the TNFerade program.